Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.50 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.50 |
| ▸ | LTA4H | P09960 | 4/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13933104 | 0.92 | MAPT (0.56) | MAPTKMT2A | |
| SCHEMBL13933102 | 0.87 | MAPT (0.52) | MAPTKMT2A | |
| SCHEMBL13933124 | 0.87 | MAPT (0.50) | MAPTKMT2APDE3BPDE3AP2RY12 | |
| SCHEMBL12480735 | 0.83 | TBXAS1 (0.60) | MAPTKMT2ACYSLTR2CYSLTR1TBXAS1 | |
| SCHEMBL11034681 | 0.83 | TBXAS1 (0.60) | MAPTKMT2ACYSLTR2CYSLTR1TBXAS1 | |
| SCHEMBL13933107 | 0.82 | CYP3A4 (0.59) | MAPTKMT2A | |
| SCHEMBL14570538 | 0.82 | MEN1 (0.59) | MAPTKMT2ACYSLTR2CYSLTR1LTA4H | |
| SCHEMBL10929179 | 0.82 | MAPT (0.69) | MAPTKMT2ATBXAS1 | |
| SCHEMBL19474670 | 0.81 | LTA4H (0.53) | MAPTCYSLTR2CYSLTR1LTA4HBRD4 | |
| SCHEMBL7747836 | 0.81 | NR5A1 (0.60) | MAPTCYSLTR2CYSLTR1LTA4HBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46144-E1 | Hydroxamic acid derivatives | PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) | 2016-09-13 | — | — | US | disclosed |
| US-RE46144-E1 | Hydroxamic acid derivatives | PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9096627-B2 | Hydroxamic acid derivatives | PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096627-B2 | Hydroxamic acid derivatives | PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140066419-A1 | HYDROXAMIC ACID DERIVATIVES | PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140066419-A1 | HYDROXAMIC ACID DERIVATIVES | PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20110269706-A1 | Hydroxamic Acid Derivatives | NORTHLAKE BIOSCIENCES LLC (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269706-A1 | Hydroxamic Acid Derivatives | NORTHLAKE BIOSCIENCES LLC (US) | 2011-11-03 | — | — | US | disclosed |
| WO-2010085377-A2 | HYDROXAMIC ACID DERIVATIVES | CRYSTAL BIOPHARMACEUTICAL LLC (US) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066419-A1 | HYDROXAMIC ACID DERIVATIVES | HDAC5, HDAC7, HDAC4 | MAPT 4527/4885KMT2A 226/4885CYSLTR2 813/4885 |
| US-20110269706-A1 | Hydroxamic Acid Derivatives | CD74, HLA-DRB1, HDAC5 | MAPT 4718/4885KMT2A 311/4885CYSLTR2 892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.